Congleton Jon 4

What Happened
Jon Congleton, a director of IMMUNIC, Inc. (IMUX), was granted a derivative award for 25,370 shares on July 5, 2026. The filing reports the acquisition price as $0.00 per share (derivative), indicating an option-style award rather than an open-market purchase. No immediate cash was paid and no shares were sold.

Key Details

• Transaction date: 2026-07-05; reported on Form 4 filed 2026-07-07 (timely filing).
• Security acquired: derivative instrument covering 25,370 shares; price reported as $0.00.
• Vesting: per footnote, the option vests in monthly increments over one year from the grant date.
• Shares owned after transaction: not specified in the filing.
• Filing status: not indicated as late.

Context
This was an award/grant (derivative) — meaning Congleton received rights to acquire shares as they vest rather than a market purchase or immediate sale. Vesting monthly over one year means the economic benefit will be realized gradually; there is no indication the options were exercised or any shares sold. Grants to directors are common forms of compensation and do not by themselves signal imminent buying or selling of stock.